{"url":"https://uneyama.hatenadiary.jp/entry/20130313/p9","categories":["EFSA"],"provider_url":"https://hatena.blog","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Funeyama.hatenadiary.jp%2Fentry%2F20130313%2Fp9\" title=\"\u30ad\u30ce\u30af\u30e9\u30df\u30f3\u306e\u65e2\u5b58MRL\u30ec\u30d3\u30e5\u30fc\u306b\u3064\u3044\u3066\u306e\u7406\u7531\u4ed8\u304d\u610f\u898b - \u98df\u54c1\u5b89\u5168\u60c5\u5831blog\u904e\u53bb\u8a18\u4e8b\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","version":"1.0","published":"2013-03-13 00:00:08","blog_url":"https://uneyama.hatenadiary.jp/","provider_name":"Hatena Blog","height":"190","blog_title":"\u98df\u54c1\u5b89\u5168\u60c5\u5831blog\u904e\u53bb\u8a18\u4e8b","width":"100%","author_name":"uneyama","description":"Reasoned opinion on the review of the existing maximum residue levels (MRLs) for quinoclamine according to Article 12 of Regulation (EC) No 396/2005 EFSA Journal 2013;11(3):3141 [11 pp.]. 12 March 2013 http://www.efsa.europa.eu/en/efsajournal/pub/3141.htm","title":"\u30ad\u30ce\u30af\u30e9\u30df\u30f3\u306e\u65e2\u5b58MRL\u30ec\u30d3\u30e5\u30fc\u306b\u3064\u3044\u3066\u306e\u7406\u7531\u4ed8\u304d\u610f\u898b","image_url":null,"type":"rich","author_url":"https://blog.hatena.ne.jp/uneyama/"}